Skip to main content
Premium Trial:

Request an Annual Quote

Acceler8 Reports Big Revenue Jump in Q2 2005

NEW YORK, March 17 (GenomeWeb News) - Acceler8's second-quarter fiscal 2005 net revenues jumped 654 percent to $241,946, from $36,968 in the same quarter in the previous year, the company said today.


The company's net loss narrowed from $474,341, or $.04 per share, in the second quarter of 2005 to $359,527, or $.03 per share, the company said.


"We expect to have the first research version [of Acceler8's Baccelr8r bacterial analyzer and monitoring system] early in calendar 2006," said David Howson, Accelr8 president.


Accelr8 did not break out its R&D spend or its cash on hand in its statement.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.